Form 4: Nuvation Bio CMO Executes Stock Option and Sale

Chief Medical Officer Dongfang Liu exercised options for 50,000 shares and subsequently sold them under a 10b5-1 trading plan.

Summary

• Dongfang Liu, Chief Medical Officer of Nuvation Bio Inc., exercised stock options for 50,000 shares of Class A Common Stock at an exercise price of $1.94 per share.
• Following the exercise, the reporting person sold the 50,000 shares at a weighted-average price of $5.02 per share.
• The sale was conducted pursuant to a pre-established Rule 10b5-1 trading plan dated December 4, 2025.
• The transaction resulted in a net reduction of the reporting person's direct holdings to 18,000 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation and liquidity, carrying no significant signal regarding company performance.

Positives

• The transaction was executed under a pre-planned 10b5-1 arrangement, indicating the sale was not based on non-public information.
• The exercise of options demonstrates the executive's participation in the company's equity incentive program.

Negatives

• The transaction represents a divestment of 50,000 shares by a key member of the executive leadership team.

Risks

• Continued reliance on Rule 10b5-1 plans for liquidity by insiders may be perceived by some investors as a signal of limited long-term holding conviction.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The filing notes that the reporting person will provide full information regarding the number of shares sold at each separate price within the $5.00 to $5.07 range upon request.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for executives to manage personal liquidity and is generally viewed as neutral by the market when pre-planned.

Comparison to Industry Standards

• The use of 10b5-1 plans is a standard corporate governance practice for executives in the biotechnology sector to avoid potential insider trading allegations.

Stakeholder Impact

• Minimal impact on shareholders as the sale was conducted through a pre-planned, automated mechanism.

Next Steps

• No future corporate actions or milestones were disclosed in this filing.

Key Dates

Keywords

Nuvation Bio, NUVB, Insider Trading, Form 4, Chief Medical Officer, Stock Options